SEC Form 4 · accession 0001127602-17-022072
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · CRL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James C Foster
Officer — Chairman, President and CEO · Director
Period of report
Jun 22, 2017
Accepted (ET)
Jun 23, 2017 · 2:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 25, 2017 | G | 4,500 | $0.00 | D | 361,178 | D | |
| Common Stock | Jun 22, 2017 | M | 43,154 | $76.67 | A | 404,332 | D | |
| Common Stock | Jun 22, 2017 | S | 43,154 | $100.00 | D | 361,178 | D | |
| Common Stock | holding | — | — | — | 340 | I | By Trust | |
| Common Stock | holding | — | — | — | 10,000 | I | Held By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $76.67 | Jun 22, 2017 | M | 43,154 | D | Feb 27, 2016 | Feb 27, 2020 | Common Stock | 43,154 | 43,154 | D |
Explanation of responses
- F1This sale occurred pursuant to a 10b5-1 Trading Plan.